Dilangani Ratnayake, MD
Interventional Pain Medicine · Palm Desert, CANPI 1992098487
Payments from drug & device makers
Across 75 payments — averaging $67.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$1K
- Boston Scientific$791
- Biohaven Pharmaceuticals, Inc.$599
- AstraZeneca$350
- Abbott$298
- Lilly USA, LLC$237
- plus $2K from 15 others
Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$16
What the payments were for
- Travel & lodging$70614%
- Food & beverage$4,37586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 17 | $1,100 |
| Boston Scientific | 15 | $791 |
| Biohaven Pharmaceuticals, Inc. | 5 | $599 |
| AstraZeneca | 3 | $350 |
| Abbott | 13 | $298 |
| Lilly USA, LLC | 2 | $237 |
| AbbVie(2 entities) | 2 | $229 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $193 |
| Novo Nordisk | 2 | $181 |
| Medtronic | 2 | $143 |
| Si-bone, Inc. | 1 | $134 |
| Boehringer Ingelheim | 1 | $125 |
| Bayer | 1 | $124 |
| Vertex | 1 | $123 |
| Amgen | 1 | $122 |
| GSK | 1 | $111 |
| SPR Therapeutics, Inc | 2 | $102 |
| Stimwave Technologies Incorporated | 1 | $62 |
| Vertiflex, Inc. | 1 | $30 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$722
- SPECTRA WAVEWRITER$439
- Omnia$266
- Senza Spinal Cord Stimulation System$262
- FARXIGA$250
- iFuse Implant$134
- UBRELVY$125
- OFEV$125
- Kerendia$124
- JOURNAVX$123
- EVENITY$122
- KISUNLA$122
- INTELLIS$119
- MOUNJARO$115
- TRELEGY ELLIPTA$111
- BOTOX$104
How this compares
$5,081 in reported general payments places this provider in the 60th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $11,229 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $1,537 |
| Buprenorphine Hcl | 12 | $6 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Palm Desert
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
- Andrew GermanovichRancho Mirage$408K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.